Letter to the editor: Clofarabine-based salvage chemotherapy for relapsed or refractory acute leukemia before allogeneic stem cell transplantation: Results from a case series

Leukemia and Lymphoma

Volumn 50, Issue 12, 2009, Pages 2071-2074

  Grigoleit, Götz Ulrich ^a   Kapp, Markus ^a   Tan, Sen Mui ^a   Unzicker, Christian ^a   Einsele, Hermann ^a   Mielke, Stephan ^a   Topp, Max S ^a   Stuhler, Gernot ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CLOFARABINE; CYCLOPHOSPHAMIDE; CYTARABINE; GEMTUZUMAB OZOGAMICIN; MELPHALAN; ADENINE NUCLEOTIDE; ANTINEOPLASTIC AGENT; ARABINONUCLEOSIDE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; BONE MARROW BIOPSY; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; DRUG TOLERABILITY; GRAFT VERSUS LEUKEMIA EFFECT; HAND FOOT SYNDROME; HUMAN; LETTER; MINIMAL RESIDUAL DISEASE; MONOTHERAPY; NEUROTOXICITY; PRIORITY JOURNAL; SALVAGE THERAPY; SIDE EFFECT; SKIN TOXICITY; TREATMENT RESPONSE; TUMOR VOLUME; ACUTE DISEASE; ACUTE MONOCYTIC LEUKEMIA; ALLOTRANSPLANTATION; CASE REPORT; DRUG RESISTANCE; FEMALE; LEUKEMIA; MALE; METHODOLOGY; MYELOID LEUKEMIA; MYELOMONOCYTIC LEUKEMIA; PATHOLOGY; RECURRENT DISEASE; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

ACUTE DISEASE; ADENINE NUCLEOTIDES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ARABINONUCLEOSIDES; CYCLOPHOSPHAMIDE; CYTARABINE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LEUKEMIA; LEUKEMIA, MONOCYTIC, ACUTE; LEUKEMIA, MYELOID; LEUKEMIA, MYELOMONOCYTIC, ACUTE; MALE; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECURRENCE; SALVAGE THERAPY; STEM CELL TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 72949094010     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428190903350413     Document Type: Letter

References (12)

1. Leopold LH, Willemze R. The treatment of acute myeloid leukemia in first relapse: A comprehensive review of the literature. Leuk Lymphoma 2002;43:1715-1727.
2. Estey E, Kornblau S, Pierce S, Kantarjian H, Beran M, Keating M. A stratification system for evaluating and selecting therapies in patients with relapsed or primary refractory acute myelogenous leukemia. Blood 1996;88:756.
3. Estey EH. Treatment of relapsed and refractory acute myeloid leukemia. Leukemia 2000;14:476-479.
4. Giralt S, Saliba RM, Rondon G, et al. Outcomes of allogeneic stem cell transplant in patients with myeloid leukemias over 65 years of age. Rationale for aggressive therapy with curative intent. Blood 2008;112(Suppl): (Abstract 2153).
5. McClune B, Weisdorf DJ, DiPErsio JF, et al. Non-myeloablative hematopoietic stem cell transplantation in older patients with AML and MDS: Results from the Center for International Blood and Marrow Transplant Research (CIBMTR). Blood 2008;112(Suppl): (Abstract 346).
6. Koca E, Saliba RM, de Lima M, et al. Impact of pretransplant cytogenetics and marrow remission status on outcome of patients with acute myeloid leukemia or myelodysplastic syndrome undergoing allogeneic stem cell transplantation conditioned with busulfan and fludarabine. Blood 2008;112(Suppl): (Abstract 341).
7. Kantarjian H, Gandhi V, Cortes J, et al. Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood 2003;102:2379-2386.
8. Faderl S, Ravandi F, Huang X, et al. A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood 2008;112:1638-1645.
9. Gidwani P, Ramesh KH, Liu Y, Kolb EA. The combination of clofarabine and cytarabine in pediatric relapsed acute lymphoblastic leukemia: A case report. Chemotherapy 2008;54:120-124.
10. Blum KA, Hamadani M, Phillips GS, et al. Prolonged myelosuppression with clofarabine in the treatment of patients with relapsed or refractory, aggressive non-Hodgkin lymphoma. Leuk Lymphoma 2009;50:349-356.
11. Martin MG, Uy GL, Procknow E, et al. Allo-SCT conditioning for myelodysplastic syndrome and acute myeloid leukemia with clofarabine, cytarabine and ATG. Bone Marrow Transplant 2009 July;44:13-17.
12. Cheson B, Vena D, Foss F, Sorensen JM. Neurotoxicity of purine analogs: A review. J Clin Oncol 1994;12:2216-2228.